Showing results (31-40 of 51) with videos related to

Sort By:
Pageof 6
The New England Journal of Medicine|September 18, 2015
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 DiabetesBernard Zinman, Christoph Wanner, John M Lachin, et al.
International Journal of Stroke : Official Journal of the International Stroke Society|January 20, 2016
European Cooperative Acute Stroke Study-4: Extending the time for thrombolysis in emergency neurological deficits ECASS-4: ExTENDHemasse Amiri, Erich Bluhmki, Martin Bendszus, et al.
The New England Journal of Medicine|September 26, 2008
Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic strokeWerner Hacke, Markku Kaste, Erich Bluhmki, et al.
Diabetes Care|December 6, 2017
How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME TrialSilvio E Inzucchi, Bernard Zinman, David Fitchett, et al.
The American Journal of Cardiology|August 11, 2014
Outcomes of a pharmacoinvasive strategy for successful versus failed fibrinolysis and primary percutaneous intervention in acute myocardial infarction (from the STrategic Reperfusion Early After Myocardial Infarction [STREAM] study)Robert C Welsh, Frans Van de Werf, Cynthia M Westerhout, et al.
Cardiovascular Diabetology|June 20, 2014
Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™)Bernard Zinman, Silvio E Inzucchi, John M Lachin, et al.
Diabetes & Vascular Disease Research|March 18, 2015
Design and baseline characteristics of the CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes (CAROLINA®)Nikolaus Marx, Julio Rosenstock, Steven E Kahn, et al.
ESC Heart Failure|October 4, 2021
Mediators of the improvement in heart failure outcomes with empagliflozin in the EMPA-REG OUTCOME trialDavid Fitchett, Silvio E Inzucchi, Bernard Zinman, et al.
International Journal of Stroke : Official Journal of the International Stroke Society|January 9, 2013
Selection for delayed intravenous alteplase treatment based on a prognostic scoreRachael L Fulton, Kennedy R Lees, Erich Bluhmki, et al.
Stroke|January 28, 2006
Outcome and symptomatic bleeding complications of intravenous thrombolysis within 6 hours in MRI-selected stroke patients: comparison of a German multicenter study with the pooled data of ATLANTIS, ECASS, and NINDS tPA trialsGötz Thomalla, Christian Schwark, Jan Sobesky, et al.
Pageof 6